There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Akebia Therapeutics (AKBA – Research Report) and Brainstorm Cell Therapeutics (BCLI – Research Report) with bullish sentiments. Akebia Therapeutics (AKBA) In a report released yesterday, Mara Goldstein from Mizuho Securities maintained a Buy rating on Akebia Therapeutics, with a price target of $6.00. The company's shares closed last Wednesday at $0.83. According to TipRanks.
https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-akebia-therapeutics-akba-and-brainstorm-cell-therapeutics-bcli?utm_source=advfn.com&utm_medium=referral
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more Brainstorm Cell Therapeu... Charts.
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more Brainstorm Cell Therapeu... Charts.